Stock info arGEN-X | Filter  Basic-Info

arGEN-X

arGEN-X primarily operates in the biotech sector. The global biotech companies gained around 59 percent worldwide over the last 10 years. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.

The past year was a good year for arGEN-X investors

Over the past year the company' stock gained around 48 percent. Over the period from December 2011 till December 2016 the stock lost on average 0 percent.

The Belgian company didn't pay out any dividends (in the past 5 years).

At the end of 2015 around 31 people were on arGEN-X' payroll.

Quite a lot of debt arGEN-X

At the end of 2015 the Belgian company's balance sheet was worth 45,96 million euros. The total debt of the biotech company was at the end of 2015 8,69 million euros, which equals around 18,91 percent of the total balance sheet. At the end of 2015 the biotech company's stock was traded with a price/earnings-ratio -8. So the stock' value was -8 times the 2015' earnings per share. We could say that based on her price/earnings-ratio and dividend yield the Belgian stock can be seen as a value stock.

At the end of 2015 the Belgian company's market capitalization equaled around 194,19 million euros. At the end of 2015 the Belgian company had around 17,34 million stocks listed on the stock exchange(s).

All arGEN-X's annual reports can be found here. More information about arGEN-X can be found it's website. .